The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Moderna and Merck reported long-term data from a mid-stage clinical trial regarding their combination therapy for skin cancer. According to the released data, the treatment combining a personalized cancer vaccine with an immunotherapy drug showed a 59% reduction in the risk of the cancer spreading to other organs. These findings come after a comprehensive five-year follow-up period for patients involved in the study.
This clinical success strengthens Merck's position in the oncology market, where its drug Keytruda remains a global top-seller, while representing a major milestone for Moderna in expanding mRNA technology beyond infectious diseases. Compared to peers, while companies like BioNTech are developing similar therapies, the 5-year data provides the Merck-Moderna alliance with a competitive edge in proving long-term efficacy per market data.
Sign in to access this content
Sign InInvestors are now watching the timeline for the commencement of Phase 3 trials which could pave the way for broad regulatory approvals. Looking at the economic calendar, while there are no direct healthcare sector events in the coming days, traders should monitor speeches from Fed officials, such as Williams on May 14, 2026, as they influence general market sentiment for growth and biotech stocks.